Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2012 1
2020 39
2021 614
2022 1104
2023 724
2024 187

Text availability

Article attribute

Article type

Publication date

Search Results

2,377 results

Results by year

Filters applied: . Clear all
Page 1
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. Meo SA, et al. Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877. Eur Rev Med Pharmacol Sci. 2021. PMID: 33629336 Free article. Review.
OBJECTIVE: The "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)" disease has caused a worldwide challenging and threatening pandemic (COVID-19), with huge health and economic losses. The US Food and Drug Administration, (FDA) has granted emergency use a …
OBJECTIVE: The "Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)" disease has caused a worldwide challenging and threatening pan …
Adverse effects of COVID-19 vaccines and measures to prevent them.
Yamamoto K. Yamamoto K. Virol J. 2022 Jun 5;19(1):100. doi: 10.1186/s12985-022-01831-0. Virol J. 2022. PMID: 35659687 Free PMC article.
Recently, The Lancet published a study on the effectiveness of COVID-19 vaccines and the waning of immunity with time. The study showed that immune function among vaccinated individuals 8 months after the administration of two doses of COVID-19 …
Recently, The Lancet published a study on the effectiveness of COVID-19 vaccines and the waning of immunity with time. …
Cutaneous adverse reactions following the Pfizer/BioNTech COVID-19 vaccine.
Luo A, Oakley A. Luo A, et al. Australas J Dermatol. 2022 Aug;63(3):e247-e250. doi: 10.1111/ajd.13859. Epub 2022 May 23. Australas J Dermatol. 2022. PMID: 35607272 Free PMC article.
A growing number of cutaneous adverse reactions have been reported following the administration of a COVID-19 vaccine. ...
A growing number of cutaneous adverse reactions have been reported following the administration of a COVID-19 …
Signaling COVID-19 Vaccine Adverse Events.
Harpaz R, DuMouchel W, Van Manen R, Nip A, Bright S, Szarfman A, Tonning J, Lerch M. Harpaz R, et al. Drug Saf. 2022 Jul;45(7):765-780. doi: 10.1007/s40264-022-01186-z. Epub 2022 Jun 23. Drug Saf. 2022. PMID: 35737293 Free PMC article.
This masking effect may in turn limit or delay our understanding of the risks associated with new and established vaccines. OBJECTIVE: The aim is to investigate the problem of masking in the context of COVID-19 vaccine signal detection, assessing its i …
This masking effect may in turn limit or delay our understanding of the risks associated with new and established vaccines. OBJECTIVE …
An Update in COVID-19 Vaccine Reactions in 2023: Progress and Understanding.
Blumenthal KG, Greenhawt M, Phillips EJ, Agmon-Levin N, Golden DBK, Shaker M. Blumenthal KG, et al. J Allergy Clin Immunol Pract. 2023 Nov;11(11):3305-3318. doi: 10.1016/j.jaip.2023.06.057. Epub 2023 Jul 4. J Allergy Clin Immunol Pract. 2023. PMID: 37414339
It has been 3 years since the coronavirus disease 2019 (COVID-19) pandemic was initially declared, and 2 years have passed since the first COVID-19 vaccines were introduced. Since then, 13.2 billion COVID-19 vaccine doses ha …
It has been 3 years since the coronavirus disease 2019 (COVID-19) pandemic was initially declared, and 2 years have passed sin …
COVID-19 vaccines mix-and-match: The concept, the efficacy and the doubts.
Rashedi R, Samieefar N, Masoumi N, Mohseni S, Rezaei N. Rashedi R, et al. J Med Virol. 2022 Apr;94(4):1294-1299. doi: 10.1002/jmv.27463. Epub 2021 Nov 30. J Med Virol. 2022. PMID: 34796525 Free PMC article. Review.
The search for developing effective vaccines against SARS-CoV-2 began with the start of the COVID-19 pandemic, and the first vaccine dose was administered in December 2020. ...Some adverse reactions have resulted in the discontinuation of the sp …
The search for developing effective vaccines against SARS-CoV-2 began with the start of the COVID-19 pandemic, and the …
Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases.
McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, Desai SR, French LE, Lim HW, Thiers BH, Hruza GJ, Blumenthal KG, Fox LP, Freeman EE. McMahon DE, et al. J Am Acad Dermatol. 2021 Jul;85(1):46-55. doi: 10.1016/j.jaad.2021.03.092. Epub 2021 Apr 7. J Am Acad Dermatol. 2021. PMID: 33838206 Free PMC article.
BACKGROUND: Cutaneous reactions after messenger RNA (mRNA)-based COVID-19 vaccines have been reported but are not well characterized. ...RESULTS: From December 2020 to February 2021, we recorded 414 cutaneous reactions to mRNA COVID-19 …
BACKGROUND: Cutaneous reactions after messenger RNA (mRNA)-based COVID-19 vaccines have been reported but are no …
Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults.
Dai L, Gao L, Tao L, Hadinegoro SR, Erkin M, Ying Z, He P, Girsang RT, Vergara H, Akram J, Satari HI, Khaliq T, Sughra U, Celi AP, Li F, Li Y, Jiang Z, Dalimova D, Tuychiev J, Turdikulova S, Ikram A, Flores Lastra N, Ding F, Suhardono M, Fadlyana E, Yan J, Hu Z, Li C, Abdurakhmonov IY, Gao GF; ZF2001 Global Trial Group. Dai L, et al. N Engl J Med. 2022 Jun 2;386(22):2097-2111. doi: 10.1056/NEJMoa2202261. Epub 2022 May 4. N Engl J Med. 2022. PMID: 35507481 Free PMC article. Clinical Trial.
A key secondary efficacy end point was the occurrence of severe-to-critical Covid-19 (including Covid-19-related death) at least 7 days after receipt of the third dose. ...Most adverse reactions (98.5%) were of grade 1 or 2. CONCLUSIONS: …
A key secondary efficacy end point was the occurrence of severe-to-critical Covid-19 (including Covid-19-related …
2,377 results